FOLD

The 'Ground Truth' for Amicus Therapeutics (FOLD) is a pending all-cash acquisition by BioMarin Pharmaceutical for $14.50 per share, expected to close in Q2 2026. The 'Bullish' technical signals (Quiet Storm, Perfect Stack) and low annualized volatility (3.6%) are not indicators of an organic breakout, but rather confirm the stock is effectively pegged to the deal price in 'Merger Arbitrage' mode. While the RISK_ON regime supports deal completion, the stock is capped at $14.50, meaning it will not participate in the broader market's 'Rocket Ship' rally.